Investors & Media

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
March 20, 2017bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Derek Adams, Ph.D. is joining the company as its Chief Technology and Manufacturing Officer and Joanne Smith-Farrell, Ph.D., is joining as Senior Vice President, Corporate Developm... 
Printer Friendly Version
March 01, 2017bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine
– Patient treated with LentiGlobinTM drug product demonstrates high levels (~50% of total hemoglobin) of anti-sickling hemoglobin (HbAT87Q) 15 months after treatment – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced... 
Printer Friendly Version
February 28, 2017bluebird bio to Present at Two Investor Conferences in March
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the following upcoming investor conferences: Cowen and Company 37th Annual Health Care Conference on Tuesday, March... 
Printer Friendly Version
February 22, 2017bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress
– Presented interim phase 1 dose escalation data for anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma at EORTC-NCI-AACR Meeting – – Presented data from clinical studies of LentiGlobinTM drug product in patients with transfusion-dependent β-thalassemia (TDT) and severe sickle cell disease (SCD) at ASH – – Treated the first patients with LentiGlobin drug product manufactured with enhanced proces... 
Printer Friendly Version
February 03, 2017bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease
- LentiGlobinTM drug product had a vector copy number (DP VCN) of 3.3 copies/diploid genome, with 83% of cells lentiviral vector sequence positive (LVV+) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first pa... 
Printer Friendly Version
January 04, 2017bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced today that Nick Leschly, chief bluebird, will present at the 35th annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 10:00 a.m. PST. The conference is being held Januar... 
Printer Friendly Version

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.